The reiteration of an Outperform rating and the maintenance of a high price target by a reputable analyst like Brian Abrahams from RBC Capital could positively influence investor sentiment towards Intra-Cellular Therapies. This endorsement suggests confidence in the company's future performance and growth prospects, potentially leading to an increase in stock price in the short term.